|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400080324 |
|
最近更新日期: Date of Last Refreshed on: |
2024-01-26 09:01:52 |
|
注册时间: Date of Registration: |
2024-01-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
辅助生殖治疗期间患者的心理特征、发展轨迹及其机制研究 |
|
Public title: |
Psychological characteristics, developmental trajectories and their mechanisms in patients during assisted reproductive treatment |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
辅助生殖治疗期间患者的心理特征、发展轨迹及其机制研究 |
|
Scientific title: |
Psychological characteristics, developmental trajectories and their mechanisms in patients during assisted reproductive treatment |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘柯显 |
研究负责人: |
刘柯显 |
|
Applicant: |
Liu Ke-Xian |
Study leader: |
Liu Ke-Xian |
|
申请注册联系人电话: Applicant telephone: |
+86 188 0397 8892 |
研究负责人电话: Study leader's telephone: |
+86 188 0397 8892 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
786644595@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
786644595@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河南省郑州市二七区康复前街7号 |
研究负责人通讯地址: |
河南省郑州市二七区康复前街7号 |
|
Applicant address: |
No. 7 Kangfuqian Street, Erqi, Zhengzhou 450052, People’s Republic of China |
Study leader's address: |
No. 7 Kangfuqian Street, Erqi, Zhengzhou 450052, People’s Republic of China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
郑州大学第三附属医院生殖医学中心 |
||
|
Applicant's institution: |
Center for Reproductive Medicine, the Third Affiliated Hospital of Zhengzhou University |
||
|
研究负责人所在单位: |
郑州大学第三附属医院生殖医学中心 |
||
|
Affiliation of the Leader: |
Center for Reproductive Medicine, the Third Affiliated Hospital of Zhengzhou University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023-102-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
郑州大学第三附属医院伦理委员会 |
||
|
Name of the ethic committee: |
The ethics committee of the Third Affiliated Hospital of Zhengzhou University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-04-28 00:00:00 |
||
|
伦理委员会联系人: |
王培 |
||
|
Contact Name of the ethic committee: |
Wang Pei |
||
|
伦理委员会联系地址: |
河南省郑州市二七区康复前街7号 |
||
|
Contact Address of the ethic committee: |
No. 7 Kangfuqian Street, Erqi, Zhengzhou 450052, People’s Republic of China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 371 6690 3091 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
郑州大学第三附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Third Affiliated Hospital of Zhengzhou University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
河南省郑州市二七区康复前街7号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 7 Kangfuqian Street, Erqi, Zhengzhou 450052, People’s Republic of China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
河南省医学科技攻关计划联合共建项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Health Commission Scientific Research Foundation Henan Medical Science and Technology Research Program Joint Construction Project |
||||||||||||||||||||||
|
Target disease: |
infertility |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
1 ART治疗患者心理弹性、生育生活质量及婚姻质量的现状及关系研究 1.1基于国内外相关研究现状,对ART治疗患者的心理弹性、生育生活质量、婚姻质量展开调查,并分析其影响因素。 1.2基于LPA探索ART治疗患者心理弹性的潜在类别特征,并分析其与生育生活质量、婚姻质量的相关性。 2 ART疗期间患者负性情绪、生育生活质量发展轨迹及其与临床结局关系的纵向研究及其机制分析 2.1 采用纵向研究设计,分析ART治疗期间患者负性情绪、生育生活质量的动态发展轨迹及其影响因素,探索患者负性情绪、生育生活质量与ART治疗临床结局的关系。 2.2 观察患者的子宫微生物群、5-HTTLPR基因多态性,分析其对患者ART治疗期间负性情绪、生育生活质量的影响特点,探索ART治疗患者心理健康的发生发展机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
1 Study on the current situation and relationship among psychological resilience, fertility quality of life and marital quality in ART-treated patients 1.1 Based on the current situation of related studies at home and abroad, we investigated the psychological resilience, reproductive quality of life and marital quality of ART-treated patients and analyzed their influencing factors. 1.2 Explore the potential category characteristics of psychological resilience of ART treatment patients based on LPA, and analyze its correlation with fertility quality of life and marital quality. 2 Longitudinal study of the developmental trajectory of patients' negative emotions and fertility quality of life during ART treatment and their relationship with clinical outcomes and its mechanism analysis 2.1 A longitudinal study design was used to analyze the dynamic trajectories of patients' negative emotions and reproductive quality of life during ART treatment and their influencing factors, and to explore the relationship between patients' negative emotions, reproductive quality of life and clinical outcomes of ART treatment. 2.2 To observe the uterine microbiota and 5-HTTLPR gene polymorphisms of patients, analyze the characteristics of their effects on patients' negative emotions and fertility quality of life during ART treatment, and explore the developmental mechanisms of mental health of ART-treated patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)根据临床标准被诊断为不孕症; (2)自愿接受辅助生殖治疗; (3)能够阅读并理解调查问卷,并能够表达自己的意愿; (4)自愿参与本研究,并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Diagnosed with infertility based on clinical criteria; (2) Voluntarily undergo assisted reproduction treatment; (3) Able to read and understand the questionnaire and to express their wishes; (4) Voluntarily participated in this study and signed the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
(1)有精神疾病史; (2)合并严重的心、脑、肺等脏器功能不全者; (3)有物质滥用/物质依赖者; (4)正在参与其他可能影响本研究的课题者(新药物、老药物新适应症、新诊疗方法、新器械、新技术的人体应用试验等)。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) A history of mental illness; (2) Those with combined severe cardiac, cerebral, pulmonary, and other organ insufficiencies (3) Those with substance abuse/substance dependence; (4) Those who are participating in other subjects that may affect this study (new drugs, new indications for old drugs, new treatment methods, new devices, new technologies for human application trials, etc.). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-01-31 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-01-31 00:00:00 至 To 2024-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
一、病例记录表:Excel 二、电子采集和管理系统:Spss、Mplus、Prism |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form: Excel Electronic Data Capture: Spss、Mplus、Prism |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |